Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines

Ki Hyun Bae,Bhuvaneshwari Shunmuganathan,Li Zhang,Andrew Lim,Rashi Gupta,Yanming Wang,Boon Lin Chua,Yang Wang,Yue Gu,Xinlei Qian,Isabelle Siang Ling Tan,Kiren Purushotorman,Paul A. MacAry,Kevin P. White,Yi Yan Yang

DOI: https://doi.org/10.1038/s41541-024-00835-x

2024-02-24

npj Vaccines

Abstract:The advent of SARS-CoV-2 variants with defined mutations that augment pathogenicity and/or increase immune evasiveness continues to stimulate global efforts to improve vaccine formulation and efficacy. The extraordinary advantages of lipid nanoparticles (LNPs), including versatile design, scalability, and reproducibility, make them ideal candidates for developing next-generation mRNA vaccines against circulating SARS-CoV-2 variants. Here, we assess the efficacy of LNP-encapsulated mRNA booster vaccines encoding the spike protein of SARS-CoV-2 for variants of concern (Delta, Omicron) and using a predecessor (YN2016C isolated from bats) strain spike protein to elicit durable cross-protective neutralizing antibody responses. The mRNA-LNP vaccines have desirable physicochemical characteristics, such as small size (~78 nm), low polydispersity index ( 90%). We employ in vivo bioluminescence imaging to illustrate the capacity of our LNPs to induce robust mRNA expression in secondary lymphoid organs. In a BALB/c mouse model, a three-dose subcutaneous immunization of mRNA-LNPs vaccines achieved remarkably high levels of cross-neutralization against the Omicron B1.1.529 and BA.2 variants for extended periods of time (28 weeks) with good safety profiles for all constructs when used in a booster regime, including the YN2016C bat virus sequences. These findings have important implications for the design of mRNA-LNP vaccines that aim to trigger durable cross-protective immunity against the current and newly emerging variants.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop lipid nanoparticle (LNP) - encapsulated mRNA vaccines that can induce long - lasting cross - protective neutralizing antibody responses against SARS - CoV - 2 and its variants. Specifically, the researchers evaluated the efficacy and safety of LNP - encapsulated mRNA booster vaccines against the Delta, Omicron variants and an ancestral virus (YN2016C, a virus isolated from bats). These vaccines aim to provide broader protection by enhancing vaccine potency to deal with the high infectivity and immune evasion ability of SARS - CoV - 2 variants.

The key points mentioned in the paper include:
- **Vaccine design**: Use LNP technology to encapsulate mRNA encoding the SARS - CoV - 2 spike protein, especially for the Delta, Omicron variants and YN2016C virus.
- **Vaccine characteristics**: The mRNA - LNP vaccine has ideal physicochemical characteristics, such as small size (about 78 nanometers), low polydispersity index (less than 0.13) and high encapsulation efficiency (more than 90%).
- **In vivo experiments**: In the BALB/c mouse model, three subcutaneous immunizations with the mRNA - LNP vaccine can achieve highly efficient cross - neutralization against the Omicron B1.1.529 and BA.2 variants for up to 28 weeks, and all constructs showed good safety when used as boosters.
- **Immune response**: The study found that using the Delta variant vaccine as the primary and first booster, followed by using the Delta, Omicron, YN2016C or SARS - CoV - 1 mRNA - LNP vaccine as the second booster, can significantly improve the cross - protective immune level against the Omicron variant.
- **Safety**: Throughout the vaccination process, no significant weight loss was observed, and blood chemistry analysis and histological analysis also did not show organ damage and inflammation, indicating that these mRNA vaccines have good safety.

In conclusion, this study provides important data support for the development of mRNA - LNP vaccines that can effectively combat current and emerging SARS - CoV - 2 variants.